Asterias Biotherapeutics, Inc. (AST) Starts Presentation at Biotech Showcase Conference

Asterias Biotherapeutics, Inc. (NYSE: AST) is engaged in the emerging field of regenerative medicine. The company’s proprietary platforms are based on its pluripotent stem cell and dendritic cell immunotherapy technologies. Asterias’ portfolio includes: AST-OPC1, currently in a phase I/IIa dose escalation clinical trial in spinal cord injury; AST-VAC1, which has demonstrated promise in a phase II study in acute myelogenous leukemia; and AST-VAC2, which represents a second generation, allogeneic approach to dendritic cell vaccines. For more information, visit the company’s website at www.asteriasbiotherapeutics.com